UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
February 4, 2019
________________
NOVO NORDISK A/S
(Exact name of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F
| Form 20-F [X] | Form 40-F [ ] |
Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
| Yes [ ] | No [X] |
If “Yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
Trading in Novo Nordisk shares by board members, executives and associated persons on 1 February 2019
Bagsværd, Denmark, 4 February 2019 — This document discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse.
The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their associated persons.
Please find below a statement of such trading in shares issued by Novo Nordisk.
As from 2004, members of Novo Nordisk's Executive Management and other members of the Senior Management Board have participated in a long-term share-based incentive programme where a proportion of the calculated shareholder value creation has been allocated to a joint pool for the participants. In 2015, seven current members of Executive Management (as well as other members of senior management) participated in the programme, where shares were allocated to the joint pool and the market value of the scheme was expensed in the accounts for 2015. In accordance with the principles of the programme, the Board of Directors of Novo Nordisk A/S on 31 January 2019 evaluated that the conditions for release of the joint pool of shares have been fulfilled. Accordingly, shares in the joint pool were transferred on 1 February 2019 to the seven current members of Executive Management as well as other current and former members of senior management. The reporting below reflects the transfer of such shares to the seven members of Executive Management.
As of 2007, a number of key employees below senior management level have also participated in a share-based programme with similar performance criteria as the programme for senior management. A programme was established for 2015, and two current Executive Vice Presidents have participated in this programme. In line with the programme for senior management, the Board of Directors of Novo Nordisk A/S on 31 January 2019 evaluated that the conditions for release of the shares have been fulfilled and the shares were transferred to the participants on 1 February 2019 accordingly. The reporting below reflects the transfer of such shares to two Executive Vice Presidents.
All employee representatives of the Board, the CEO and the Executive Vice Presidents have participated in a general employee share program in 2016 where 50 shares have been transferred to the participants on February 1, 2019.
Page 2 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Mette Bøjer Jensen | |
| 2 | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors (employee representative) | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 3 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Anne Marie Kverneland | |
| 2 | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors (employee representative) | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 4 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Thomas Rantzau | |
| 2 | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors (employee representative) | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 5 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Stig Strøbæk | |
| 2 | Reason for the notification | ||
| a) | Position/status | Member of the Board of Directors (employee representative) | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 6 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |
| 2 | Reason for the notification | ||
| a) | Position/status | President and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 17,650 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 17,650 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 7 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Lars Fruergaard Jørgensen | |
| 2 | Reason for the notification | ||
| a) | Position/status | President and CEO | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 8 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Jesper Brandgaard | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Biopharm and Legal Affairs | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 21,768 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 21,768 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 9 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Jesper Brandgaard | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Biopharm and Legal Affairs | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 10 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Jesper Brandgaard | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Biopharm and Legal Affairs | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 315.84 | 21,768 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 21,768 shares | ||
| - Price | DKK 315.84 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
Page 11 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, International Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 8,679 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 8,679 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 12 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Maziar Mike Doustdar | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, International Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 13 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Lars Green | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Business Services & Compliance | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 8,679 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 8,679 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 14 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Lars Green | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Business Services & Compliance | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 15 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Lars Green | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Business Services & Compliance | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 315.21 | 6,000 shares | ||
| DKK 317.38 | 627 shares | ||
| DKK 317.35 | 174 shares | ||
| DKK 317.35 | 419 shares | ||
| DKK 317.38 | 627 shares | ||
| DKK 317.38 | 627 shares | ||
| DKK 317.35 | 247 shares | ||
| DKK 317.35 | 8 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 8,729 shares | ||
| - Price | DKK 315.88 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
Page 16 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, chief financial officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 7,763 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 7,763 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 17 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, chief financial officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 18 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Karsten Munk Knudsen | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, chief financial officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 317.45 | 3,000 shares | ||
| DKK 317.40 | 3,000 shares | ||
| DKK 317.45 | 1,813 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 7,813 shares | ||
| - Price | DKK 317.43 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
Page 19 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Doug Langa | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, North America Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 2,600 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 2,600 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 20 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Doug Langa | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, North America Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 21 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Doug Langa | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, North America Operations | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 315.80 | 910 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 910 shares | ||
| - Price | DKK 315.80 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
Page 22 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Commercial Strategy & Corporate Affairs | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 2,500 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 2,500 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 23 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Camilla Sylvest | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Commercial Strategy & Corporate Affairs | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 24 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Mads Krogsgaard Thomsen | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, chief science officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 21,768 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 21,768 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 25 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Mads Krogsgaard Thomsen | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, chief science officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 26 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Mads Krogsgaard Thomsen | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, chief science officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Sale of shares | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 315.71 | 22,178 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 22,178 shares | ||
| - Price | DKK 315.71 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
Page 27 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Signe Krogsgaard Gudnason | |
| 2 | Reason for the notification | ||
| a) | Position/status | Associated to Mads Krogsgaard Thomsen, EVP, Chief Science Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Purchase of shares | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 315.71 | 205 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 205 shares | ||
| - Price | DKK 315.71 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
Page 28 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Sebastian Krogsgaard Gudnason | |
| 2 | Reason for the notification | ||
| a) | Position/status | Associated to Mads Krogsgaard Thomsen, EVP, Chief Science Officer | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Purchase of shares | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 315.71 | 205 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 205 shares | ||
| - Price | DKK 315.71 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Nasdaq Copenhagen | |
Page 29 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Henrik Wulff | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Product Supply | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with long-term incentive programme) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 11,687 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 11,687 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 30 of 32
| 1 | Details of the person discharging managerial responsibilities/person closely associated | ||
| a) | Name of the Board member/Executive/Associated Person | Henrik Wulff | |
| 2 | Reason for the notification | ||
| a) | Position/status | EVP, Product Supply | |
| b) | Initial notification/Amendment | Initial notification | |
| 3 | Details of the issuer | ||
| a) | Name | Novo Nordisk A/S | |
| b) | LEI | 549300DAQ1CVT6CXN342 | |
| 4 | Details of the transaction(s) | ||
| a) | Description of the financial instrument, type of instrument, | Shares | |
| Identification code | Novo Nordisk B DK0060534915 | ||
| b) | Nature of the transaction | Other transaction (transfer of shares in accordance with a general employee share programme (restricted shares)) | |
| c) | Price(s) and volume(s) | ||
| Price(s) | Volume(s) | ||
| DKK 0.00 | 50 shares | ||
| d) | Aggregated information | ||
| - Aggregated volume | 50 shares | ||
| - Price | DKK 0.00 | ||
| e) | Date of the transaction | 1 February 2019 | |
| f) | Place of the transaction | Outside a trading venue | |
Page 31 of 32
Definitions and background information:
Publication
Publication shall take place no later than three working days after the trading by board members, executives or their associated persons. Publication is only required when the total amount of transactions of a specific board member/executive or his/her associated persons in any one calendar year has reached EUR 20,000 (calculated individually).
Who are board members, executives and associated persons?
Board members and executives are members of the Board of Directors and Executive Management, respectively, of Novo Nordisk A/S. Associated persons are defined as the following persons associated to a board member/executive: 1) spouse or cohabitant, 2) children under the age of 18 years, 3) Other relatives defined as brothers, sisters, parents, grandparents, children, grandchildren, cousins etc. who have shared the same household with a board member or executive for a period of at least one year on the date of the given transaction and 4) any legal persons, trust, or partnership, the managerial responsibilities of which are discharged by a board member/executive or by a person referred to in items 1)-3) above, or which is directly or indirectly controlled by such a person, or which is set up for the benefit of such a person, or the economic interests of which are substantially equivalent to those of such a person.
What is trading/transaction?
Trading is any kind of transaction, including shares and share related securities purchased or otherwise acquired, sold or otherwise disposed, gifts, mortgages, heritage and grants, allotments and exercise of options.
What is financial instrument and ID code?
Financial instrument includes shares listed on the Nasdaq Copenhagen and ADRs listed on New York Stock Exchange, except for ADRs held in 401(k) retirement plan by US-based employees. The ID code is the code (ISIN DK0060534915) of the Novo Nordisk share on the Nasdaq Copenhagen or the code (NVO) on New York Stock Exchange.
What is date and place of transaction?
Date of transaction is the actual transaction date. The place of transaction is the actual place of transaction, i.e. Nasdaq Copenhagen or New York Stock Exchange.
What is the volume and price of transaction and aggregated information?
The volume of transaction is the number of shares (of DKK 0.20 nominal value) or other financial instruments traded. In case of a single transaction the price is the price of that single transaction. In case of multiple transactions, when the transactions relates to the same financial instrument, are of the same nature, are executed on the same day and are executed on the same place, the volume must be aggregated. The price of the aggregated transactions is the weighted average price.
Page 32 of 32
The exchange rate of the Danish Central Bank (Nationalbanken) on the date of transaction is used for calculating the transaction value in DKK in case of ADRs listed on New York Stock Exchange.
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, haemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 43,200 people in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn, YouTube.
Further information
| Media: | ||
| Mette Kruse Danielsen | +45 4442 3883 | krsp@novonordisk.com |
| Ken Inchausti (US) | +1 609 240 9429 | kiau@novonordisk.com |
| Investors: | ||
| Peter Hugreffe Ankersen | +45 3075 9085 | phak@novonordisk.com |
| Anders Mikkelsen | +45 3079 4461 | armk@novonordisk.com |
| Valdemar Borum Svarrer | +45 3079 0301 | jvls@novonordisk.com |
| Kristoffer Due Berg | +45 3079 2849 | krdb@novonordisk.com |
| Ann Søndermølle Rendbæk | +45 3075 2253 | arnd@novonordisk.com |
Novo Nordisk A/S Investor Relations |
Novo Allé 2880 Bagsværd Denmark |
Telephone: +45 4444 8888 |
Internet: 24 25 67 90 |
| Company announcement No 7 / 2019 | |||
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
| Date: February 4, 2019 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen Chief Executive Officer |